Molecular testing (PCR antigen testing) on a single throat with deep nasal swab is the current test of choice for the diagnosis of acute COVID 19 infection.

COVID-19 IgG/IgM (antibody) rapid tests have no role to play in the acute diagnosis of COVID-19 virus infection.

The NMRA reviews and grants market authorizations/ waivers of registration to PCR antigen tests after careful validation by relevant experts.

The NMRA will accept market authorization applications for IgG/IgM (antibody) rapid tests. These rapid tests will be reviewed by the Authority and will also be subjected to validation by relevant experts. However, market authorizations/ waivers of registration will be granted ONLY after relevant experts decide on their appropriate use in the laboratory/community setting.

Published on 06/04/2020